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OBJECTIVE: To determine whether the incidence of fe-
brile leucopenia (FL) is reduced in SCLC patients by ad-
ministering prophylactic antibiotics thereby reducing re-
source use and costs associated with treatment.
METHODS: A cost-effectiveness analysis was conducted
alongside a multicenter phase III randomized controlled
trial with a 2  2 factorial design. The trial was designed to
compare standard dose CDE (cyclophosphamide, dox-
orubucin and etoposide) versus intensified CDE (125%
dose with G-CSF), with or without prophylactic antibiot-
ics. Patients in the verum arm received roxithromycin
150 mg and ciprofloxacin 750 mg, both given twice daily
for 10 days, commencing the day after completing each
cycle of chemotherapy. The economic evaluation examines
the costs and effects of patients taking antibiotics versus
placebo. Results are presented for 33 patients in The Neth-
erlands, representing 20.5% of the total sample (n  161).
Resource utilization data were collected during the trial
and included hospitalizations, concomitant medications,
transfusions and medical procedures. The viewpoint of the
health insurance system is taken, using 1998 prices ex-
pressed in Dutch guilders (ppp of 2.07NLG/US$). The ef-
fectiveness measures include the incidence of febrile leu-
copenia and the number of infectious deaths.
RESULTS: The average cost attributed to patients in the
placebo arm was 12,898 NLG compared to 6,999 NLG in
the verum arm, yielding a difference of 5,899 NLG (US$
2850) (95% CI () 2081  13,897) in favor of administer-
ing prophylactic antibiotics. The clinical trial (n  161)
demonstrated a 50% decrease in the incidence of FL and an
absolute reduction in the risk of infectious death from 6%
to 0% in patients taking antibiotics.
CONCLUSION: The use of prophylactic antibiotics in
small cell lung cancer patients is cost-effective as it reduces
the incidence of FL and infectious deaths whilst reducing
direct medical costs by 45%. This study was partly spon-
sored by Bayer BV.
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OBJECTIVES: To compare the direct costs of managing
patients with advanced colorectal cancer in five European
countries by means of a resource use index, which avoids
the confounding caused by differences in absolute and rela-
tive prices.
METHODS: In 10 hospitals in five countries, data on pa-
tient management and resource use were collected from the
hospital charts of 20 consecutive, newly diagnosed pa-
tients. All available data on resource use for each patient
from diagnosis until death or last seen alive were included
in the investigation. For only one country, Belgium, was it
possible to find a complete set of consistent unit prices,
namely the tariffs according to which the providers are re-
munerated by the health insurance system. By using these
unit prices to value the use of resources in all countries, an
index for average total resource use per hospital has been
constructed, which reflects only differences in real resource
utilization. The average across all the hospitals has been set
equal to 100, so index values represent deviations from this
average.
RESULTS: The estimated index values for average total re-
source use vary from 75 to 131. Differences between the
two hospitals in each country are just as big as those be-
tween hospitals in different countries. When subdividing
the patients into four types according to site and stage of
disease, the spread between the hospitals becomes even
wider. No hospital is consistently above or below the aver-
age resource use for all patient categories.
CONCLUSIONS: Superficial comparisons of the costs of
treating specific diseases in different countries will unavoid-
ably be confounded by differences in prices. By using a sin-
gle set of unit prices for weighting the use of resources, an
index reflecting only real differences in resource use may be
determined and used for initial, aggregate comparisons ex-
ploring the need for further analysis.
CA3
ESTIMATING SURVIVAL GAIN FOR 
COST-EFFECTIVENESS ANALYSIS: THE 
EXAMPLE OF EARLY HORMONAL TREATMENT 
IN LOCALLY ADVANCED PROSTATE CANCER
Neymark N, Adriaenssen I, Caleo S
EORTC Health Economics Unit, Brussels, Belgium
OBJECTIVES: To examine the impact of various meth-
ods of estimating survival gain from censored survival
data on the results of a cost-effectiveness analysis.
METHODS: A cost-effectiveness analysis of the addition
to radiotherapy of early hormonal therapy with a LHRH
analogue (goserelin) in patients with locally advanced
prostate cancer has been carried out. The clinical results
derive from a randomized controlled trial (EORTC
22863, reported by Bolla et al. [1]), and resource utiliza-
tion data were collected retrospectively in one French
hospital recruiting 90/415 patients in the trial. Costs are
calculated from the viewpoint of the French health insur-
ance system. To estimate average survival, various meth-
ods are available and will be compared, notably a re-
stricted means analysis truncated at a median follow-up
of 45 months and extrapolations based on fitting a para-
metric model (e.g., Weibull or exponential) to the sur-
vival curves.
RESULTS: The clinical trial documented an overall sur-
vival rate at 5 years of 79% in the group receiving radio-
therapy plus hormonal therapy compared to 61% (p 
0.001) in those receiving only radiotherapy. The average
costs in the two groups were 81,700 FF and 69,900 FF
respectively. The survival improvement is thus associated
with an increase of 11,800 FF in average cost, but to de-
termine the incremental cost-effectiveness ratio (ICER)
the exact gain in average survival must be known. The re-
